Epstein-Barr virus (EBV)-associated B-lymphoproliferative disorder (BLPD) in the setting of autologous stem cells transplantation (ASCT) is described mainly as case histories. [1] [2] [3] [4] [5] [6] The purine analogues as new treatment modalities with enhanced immunosuppressive effect have the capacity to promote EBV reactivation and transformation to lymphoproliferative disorder as recently demonstrated. [7] [8] [9] Moreover, this risk could theoretically be even more pronounced if ASCT follows the treatment with purines. We report on two patients with CLL in whom EBV-BLPD developed after therapy with fludarabine monophosphate (Flu) and cycloclophosphamide (Cy) followed directly by ASCT. From 1998, in our department, all patients with CLL with risk factors-defined as Rai stage III-IV or adverse cytogenetics, rapid doubling time, diffuse marrow infiltration pattern-entered the study in which they were treated upfront according to the following protocol: Flu 25 mg/m CD34+cells/kg harvested), the patients proceeded directly to ASCT after conditioning with Cy (50 mg/kg for four consecutive days, i.e. 200 mg/kg total dose). From 1998, 46 patients completed the protocol. Of these, 22 of them underwent ASCT. In 24 patients, the mobilization failed and they were treated with Flu-Cy only. In the group of patients who completed the whole protocol, we unexpectedly experienced clustering of two cases of EBV-BLPD. Patient 1 was a 57-year-old male diagnosed as having CLL stage I Rai in November 1996. In August 1998, disease progression was noted and because of the rapid doubling time the patient entered the Flu-Cy-ASCT protocol. Cytogenetic analyses revealed normal karyotype; EBV was seropositive. A nodular PR was attained after four cycles of Flu-Cy and 3 months later, he was successfully mobilized with the yield of 11.52 Â 10 6 CD34+ cells/kg. High-dose Cy followed by PBSC infusion started 1 month after harvest. Haematological recovery was fast and uneventful and on restaging the attainment of complete remission according to NCI criteria 10 was established. Furthermore, negative FACS and IgH rearrangement studies were consistent with immunophenotypic and molecular CR. At 5 months after ASCT, he developed progressive generalized adenomegaly and splenomegaly accompanied with fever. One cycle of CHOP chemotherapy was urgently applied because of presumed CLL relapse. However, the patient deteriorated rapidly and died on day +170. The bone marrow (BM) as well as FACS analysis showed no signs of CLL. Lymph node biopsies allowed a histological diagnosis of posttransplant lymphoproliferative disorder of polymorphic type. Immunohistochemistry studies demonstrated B-cell phenotype, monoclonality and positive stain for EBV-LMP1 (latent membrane protein; 1:25 monoclonal mouse antibody, clones CS 1-4, Dako, Glostrup, Denmark). The diagnosis of EBV-BPLD was further supported by positive PCR (DNA from PB, BM, lymph node) using different sets of primers for Epstein-Barr encoded RNA (EBER) and Epstein-Barr nuclear antigen (EBNA). 11, 12 At autopsy, there was no evidence of CLL and all histological findings from enlarged lymph nodes were in agreement with the diagnosis of polymorphic type of EBV-LPD.
Patient 2 was a male aged 49 years with Rai stage II CLL with a normal karyotype. Serological tests for EBV were positive. The patient was treated from March 1999 according to the protocol, and after four cycles of FluCy he entered nodular PR, and 2 months after the last chemotherapy, he was successfully mobilized (2.73 Â 10 6 CD 34+ cells/kg). High-dose chemotherapy with stem cell reinfusion was given immediately with an uneventful posttransplant period. The restaging 1 month after transplantation showed partial nodular remission, with no sign of disease in lymph nodes, spleen, and liver. At 2 months after ASCT, mediastinal and cervical adenomegaly developed abruptly. BM was negative on cytology and residual CLL nodules corresponded histologically with continuing nodular PR. Immunophenotypic analyses corroborated the presence of residual disease only. Surprisingly, lymph node biopsy showed a B-lineage LPD of monomorphic, diffuse large cell-type. An immunohistochemistry stain for EBV-LPD was inconclusive, but EBER and EBNA were again detected by PCR as in the previous case. The adenomegaly rapidly progressed to respiratory insufficiency requiring ventilatory support and the patient died on day +75 after ASCT, before the results of the tests were available. Autopsy was not performed. Serological tests for EBV in both the patients were not repeated after ASCT.
The upfront treatment of CLL patients with purine analogues is becoming standard, 13 at least for high-risk groups. However, the role of ASCT as consolidation remains controversial. These cases demonstrate the significant level of immune suppression after our treatment protocol and thus confirm the potential of combination therapy containing purine analogues to reactivate a latent EBV infection, as Lazzarino et al 8 convincingly showed and others described in case reports. 10, 12 The addition of another agent with additional immunosuppressive effect such as, for example, cyclophosphamide in our study or corticoids may increase this risk. Our series of patients suggests the possible causative role of the increased exposure to the Cy besides FAMP administration. Interestingly, no cases of EBV-BPLD occurred in the group of 24 patients with mobilization failure, that is, in patients exposed to the same number of Flu-Cy regimens (median four cycles in both groups, data not shown) and Cy 3 g/m as mobilizing agent but omitting the Cy conditioning (200 mg/kg total Cy dose). Notably, Cy used in conditioning is more immunablative than myeloablative. However, the exclusive occurrence of EBV-BLPD only in the group of 22 patients completing the whole protocol did not reach statistical significance (P ¼ 0.22). Considering the limited statistical power in our small group of patients this does not exclude the possible key role of the repeated Cy exposure (ie for mobilization and conditioning) after standard FluCy in the EBV-PTLD development. The serial quantitative determinations of the circulating EBV DNA load as Lazzarino et al suggested 8 could perhaps illustrate the putative role of the Cy conditioning in our patients, but we did not perform such testing.
We feel that it is of utmost importance to provide unquestionable evidence of the real presence of EBV-BLPD in our cases. Firstly, the relapse of CLL must be unequivocally excluded. This possibility seems to be unlikely, given the good response to the Flu-Cy-ASCT treatment and the prompt progression of lymphadenopathy on the contrary in the short period after ASCT. Particularly, the absence of CLL cells in the BM in both cases does not correspond to the natural course of disease. Secondly, the diagnosis of EBV-BLPD is intensely supported by the typical histological findings, the detection of LMP at least in patient 1 and the positivity of EBV-DNA by different PCR techniques. The specificity of the latter could be challenged, especially in the patient 2 where immunohistochemistry was not fully conclusive for EBV. However, the diagnostic potency of PCR testing in our cases is underlined by the consistent EBV-DNA negativity in the retrospectively tested samples taken at diagnosis and during treatment in both the patients. In summary, we consider all the above-mentioned tests as compelling and overwhelming evidence for EBV-BLPD in our cases. EBV-BLPD in these autologous transplant patients occurred 2 and 5 months after ASCT, that is, earlier than typical onset after allogeneic bone marrow transplantation. This time-frame is in agreement with previously described cases of EBV-BLPD after purine analogues 7, 9 or after ASCT 1-6 and according to Lones et al 6 reflects earlier immune system recovery in the ASCT setting. The outcome in these patients was poor. Recently, encouraging results have been demonstrated with anti-CD-20 monoclonal antibody.
14 However, this treatment was not applied to our patients primarily because of the fact that diagnosis of EBV-LPD was missed in vivo. Simply, the relapse of CLL was presumed and the rapid progression obviates the possible effective therapy of the disease and caused the fact that the definitive diagnosis of EBV-BLPD was established post mortem.
In conclusion, our case series indicates that EBV-BLPD should be counted as a real risk when treating the CLL patients with purine analogues and high-dose chemotherapy with ASCT and increased suspicion of it with appropriate testing should be considered in this setting. 
